ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Biogen Idec has agreed to acquire Fumapharm AB, a Swiss developer of therapeutics derived from fumaric acid esters, for an undisclosed sum. The two firms also announced positive results from a Phase II study of BG-12, an oral fumarate they are jointly developing for the treatment of multiple sclerosis and psoriasis. As part of a restructuring last year, Biogen Idec announced plans to actively pursue relationships with other firms and academic institutions (C&EN, Sept. 19, 2005, page 9). Earlier this year, the company announced plans to acquire Conforma Therapeutics for $150 million.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter